复星医药(02196)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

02196 复星医药

交易中 06-17 13:03:40

15.940

-0.160

-0.99%

最高16.190	最低15.840	成交量53.00万
今开16.120	昨收16.100	日振幅2.17%
总市值423.84亿	流通市值86.23亿	总股本26.59亿
成交额846.23万	换手率0.10%	流通股本5.41亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"02196","market":"HK","secType":"STK","nameCN":"复星医药","latestPrice":15.94,"timestamp":1781672576715,"preClose":16.1,"halted":0,"volume":530000,"delay":0,"changeRate":-0.009937888198757882,"floatShares":540971500,"shares":2659000000,"eps":1.27,"marketStatus":"交易中","change":-0.16,"latestTime":"06-17 13:03:40","open":16.12,"high":16.19,"low":15.84,"amount":8462335,"amplitude":0.021739,"askPrice":15.95,"askSize":16500,"bidPrice":15.9,"bidSize":4000,"shortable":3,"etf":0,"ttmEps":1.488877,"tradingStatus":2,"nextMarketStatus":{"tag":"收盘","tradingStatus":0,"beginTime":1781683800000},"marketStatusCode":2,"adr":0,"listingDate":1351526400000,"exchange":"SEHK","adjPreClose":16.1,"dividendRate":0.021957,"openAndCloseTimeList":[[1781659800000,1781668800000],[1781672400000,1781683200000]],"volumeRatio":0.436387,"lotSize":500,"spreadScale":0,"tradeCurrency":"HKD","astockBrief":{"symbol":"600196","market":"SH","secType":"STK","nameCN":"复星医药","latestPrice":21.59,"timestamp":1781672616000,"preClose":21.85,"halted":0,"volume":11012400,"delay":0,"premium":"-36.33"}},"requestUrl":"/m/hq/s/02196","defaultTab":"news","newsList":[{"id":"2644989837","title":"捡漏“弃药”押注联合疗法应世生物深度捆绑“复星系”闯关港交所","url":"https://stock-news.laohu8.com/highlight/detail?id=2644989837","media":"经济参考报","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2644989837?lang=zh_cn&edition=full","pubTime":"2026-06-17 04:50","pubTimestamp":1781643034,"startTime":"0","endTime":"0","summary":"曾被跨国药企勃林格殷格翰弃用的FAK抑制剂，如今成了应世生物（InxMedLimited）冲刺港股18A的核心筹码。这家企业低价接手海外“弃药”，跳出行业过往“单药治疗”路径，主打联合疗法，将FAK抑制剂作为“基石药物”嵌套进化疗/ADC/免疫治疗的组合方案中，试图实现资产价值重估。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202606173773483484.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202606173773483484.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK1191","BK0239","BK0028","BK0196","BK0175","PROC","BK1515","600196","BK4007","02196","BK0188","BK0012","BK0183","BK1593","BK0060","BK0096","BK0187"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2643676884","title":"复星医药(02196)将于8月14日派发末期股息每股0.39元","url":"https://stock-news.laohu8.com/highlight/detail?id=2643676884","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2643676884?lang=zh_cn&edition=full","pubTime":"2026-06-16 21:38","pubTimestamp":1781617127,"startTime":"0","endTime":"0","summary":"智通财经APP讯，复星医药(02196)发布公告，该公司将于2026年8月14日派发截至2025年12月31日止年度的末期股息每股0.39元。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1455199.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["600196","BK1191","BK0196","BK4585","BK0188","BK0012","VIG","BK0183","BK0060","02196","BK0096","BK0239","BK4588","BK0175","BK0187","BK1593","BK1515","BK0028"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1179021606","title":"复星医药更新末期股息派发方案：每股0.45港元，8月14日派息","url":"https://stock-news.laohu8.com/highlight/detail?id=1179021606","media":"公告速递","labels":["SGX"],"top":1,"itemType":null,"share":"https://www.laohu8.com/m/news/1179021606?lang=zh_cn&edition=full","pubTime":"2026-06-16 21:31","pubTimestamp":1781616685,"startTime":"0","endTime":"0","summary":"复星医药公布截至2025年12月31日止年度末期股息的更新派息安排，宣派普通股息为每股0.39元人民币，将以每股0.45港元派付，汇率按1元人民币兑1.1503港元计算。股东周年大会已于2026年6月16日批准该方案。此次分派的除净日为2026年7月16日，递交股份过户文件的截止时间为7月17日16:30，暂停办理股份过户登记手续的日期为7月20日至7月24日，记录日期为7月24日，股息派发日为2026年8月14日。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"复星医药更新末期股息派发方案：每股0.45港元，8月14日派息","news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02196"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1127755812","title":"复星医药宣派末期股息每股0.39元，H股每股0.45港元","url":"https://stock-news.laohu8.com/highlight/detail?id=1127755812","media":"公告速递","labels":["SGX"],"top":1,"itemType":null,"share":"https://www.laohu8.com/m/news/1127755812?lang=zh_cn&edition=full","pubTime":"2026-06-16 21:25","pubTimestamp":1781616347,"startTime":"0","endTime":"0","summary":"复星医药于2026年6月16日举行股东周年大会，正式批准派发截至2025年12月31日止年度的末期股息，每股人民币0.39元（税前）。根据公告，此次股息将向A股股东以人民币支付，向H股股东以港币支付。为确定有权收取H股末期股息的股东名单，公司将于2026年7月20日至2026年7月24日暂停办理H股股份过户登记手续。在预扣税安排方面，公司将为H股非居民企业股东代扣代缴10%的企业所得税。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"复星医药宣派末期股息每股0.39元，H股每股0.45港元","news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02196"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1108470670","title":"复星医药Luvometinib片新增适应症药品注册申请获国家药监局批准","url":"https://stock-news.laohu8.com/highlight/detail?id=1108470670","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1108470670?lang=zh_cn&edition=full","pubTime":"2026-06-15 20:29","pubTimestamp":1781526556,"startTime":"0","endTime":"0","summary":"上海复星医药（集团）股份有限公司宣布，其Luvometinib片新增适应症的药品注册申请已正式获得中国国家药品监督管理局的批准。此次获批标志着该药物在已获准的适应症基础上，其治疗范围将进一步扩大，有望惠及更广泛的患者群体。Luvometinib片是一种创新药物，此次新增适应症的批准，不仅丰富了公司的产品管线，也为其在相关治疗领域的市场拓展提供了新的动力。公司将继续推进该药物的后续研发及商业化进程，以满足临床未尽的医疗需求。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1593","BK0012","BK0187","BK0060","BK0183","BK0188","BK0239","BK1515","600196","BK0175","02196","BK0028","BK0096","BK1191","BK0196"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2643208779","title":"9.68亿元“补血”：复星医药子公司复星安特金增资扩股","url":"https://stock-news.laohu8.com/highlight/detail?id=2643208779","media":"财中社","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2643208779?lang=zh_cn&edition=full","pubTime":"2026-06-15 19:41","pubTimestamp":1781523660,"startTime":"0","endTime":"0","summary":"6月15日，复星医药（600196/02196）发布公告，控股子公司复星安特金拟以每股84.207235元的价格向4方投资人新增发行合计1150万股股份，约占本次增资扩股后复星安特金股份总数的12.15%。其中，外部投资人拟出资合计4.18亿元认购共计496万股，公司控股子公司复星医药产业（复星安特金之直接控股股东）拟出资5.5亿元认购653万股。本次增资扩股不构成关联交易。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202606153771725887.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK0028","BK0060","BK0183","BK0175","BK0187","BK0188","BK0096","BK1191","600196","BK1593","BK0012","BK0196","BK1515","BK0239","02196"],"isVideo":false,"video":null,"gpt_icon":1},{"id":"2643270025","title":"复星医药最新公告：控股子公司药品芦沃美替尼片新增适应症获国家药监局批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2643270025","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2643270025?lang=zh_cn&edition=full","pubTime":"2026-06-15 19:19","pubTimestamp":1781522392,"startTime":"0","endTime":"0","summary":"复星医药(600196.SH)公告称，公司控股子公司上海复星医药产业发展有限公司的药品芦沃美替尼片(商品名：复迈宁)新增适应症的药品注册申请获国家药监局批准，本次获批的新适应症为用于2岁及2岁以上经系统治疗后复发或难治的朗格汉斯细胞组织细胞增生症(LCH)儿童及青少年患者。该药品为本集团自主研发的MEK1/2选择性抑制剂，截至公告日，累计研发投入约6.99亿元。以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。相关 ETF","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026061500028452.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1191","02196","BK0175","BK0188","BK0060","BK0028","BK0183","BK0187","BK1515","BK1593","600196","BK0239","BK0096","BK0012","BK0196"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642469217","title":"复星医药最新公告：斯鲁利单抗注射液新适应症获国家药监局批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2642469217","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2642469217?lang=zh_cn&edition=full","pubTime":"2026-06-09 18:10","pubTimestamp":1780999822,"startTime":"0","endTime":"0","summary":"复星医药(600196.SH)公告称，公司控股子公司复宏汉霖自主研发的斯鲁利单抗注射液新增适应症获国家药监局批准，本次获批适应症为联合奥沙利铂和替吉奥用于肿瘤PD-L1表达CPS≥5的可手术切除的胃癌新辅助及手术后单药辅助治疗。该药品为全球首个在胃癌围术期以免疫单药替代术后辅助化疗的治疗方案，有助于增强市场竞争力。以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。相关 ETF","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026060900029768.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1593","BK0187","BK1191","BK0175","BK1515","BK0239","BK0096","600196","BK0188","BK0028","BK0196","BK0012","02196","BK0060","BK0183"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642452239","title":"复星医药等在济南成立新合伙企业","url":"https://stock-news.laohu8.com/highlight/detail?id=2642452239","media":"南方财经网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2642452239?lang=zh_cn&edition=full","pubTime":"2026-06-09 14:25","pubTimestamp":1780986300,"startTime":"0","endTime":"0","summary":"南方财经6月9日电，天眼查App显示，近日，济南市复惠星未来医疗投资管理合伙企业（有限合伙）成立，执行事务合伙人为上海复星平耀投资管理有限公司，出资额7501万人民币，经营范围为以自有资金从事投资活动、企业管理、信息咨询服务。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202606093765046282.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK0196","BK0183","BK0239","02196","BK0060","600196","BK0175","BK1191","BK0012","BK1515","BK0188","BK0187","BK1593","BK0028","BK0096"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2641611953","title":"复星医药：向权益分派实施公告指定的股权登记日可参与分配的股东每10股派发现金红利人民币3.90元（税前）","url":"https://stock-news.laohu8.com/highlight/detail?id=2641611953","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2641611953?lang=zh_cn&edition=full","pubTime":"2026-06-05 17:18","pubTimestamp":1780651117,"startTime":"0","endTime":"0","summary":"证券之星消息，复星医药(600196)06月05日在投资者关系平台上答复投资者关心的问题。投资者提问：啥时分红，亏大发了，尽快分红复星医药回复：投资者您好！公司2025年度利润分配预案尚待2025年度股东会（将于2026年6月16日召开）批准，本次利润分配预案为向权益分派实施公告指定的股权登记日可参与分配的股东每10股派发现金红利人民币3.90元（税前）。有关本次分红的具体安排，请留意公司后续发布的临时公告。感谢您对公司的关注。本文数据来源于上海证券交易所e互动，仅供参考不构成投资建议。相关 ETF","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026060500029774.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0175","BK0239","UCmain","BK0060","BK1515","BK0196","BK0187","BK0096","CNHmain","BK0183","MUCmain","MCNHmain","BK0012","BK1593","600196","BK0028","CYB","BK0188","BK1191","02196"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1128122169","title":"复星医药更新2026年5月股份变动月报表，股本维持稳定","url":"https://stock-news.laohu8.com/highlight/detail?id=1128122169","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1128122169?lang=zh_cn&edition=full","pubTime":"2026-06-04 16:32","pubTimestamp":1780561924,"startTime":"0","endTime":"0","summary":"上海复星医药(集团)股份有限公司于2026年6月4日发布2026年5月股份变动月报表，披露了截至2026年5月31日的股本情况。本报告期内，公司法定注册股本维持在人民币2,670,429,325元，其中H股为551,940,500股，A股为2,118,488,825股，面值均为人民币1元。同时，公司2025年H股受限制股份单位计划已授出但尚未归属的受限制股份单位为10,382,200份，与上期一致。公司表示，已遵守香港联合交易所有限公司上市规则及相关法律法规的规定。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02196"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640970576","title":"复星医药：2025年及2026年第一季度业绩稳健增长","url":"https://stock-news.laohu8.com/highlight/detail?id=2640970576","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2640970576?lang=zh_cn&edition=full","pubTime":"2026-06-03 17:12","pubTimestamp":1780477944,"startTime":"0","endTime":"0","summary":"证券之星消息，复星医药06月03日在投资者关系平台上答复投资者关心的问题。得益于创新研发与国际化运营的深度耦合，公司2025年及2026年第一季度业绩稳健增长。2025年8月公告的新一期股权激励方案中也明确2025年至2027年归母净利润及创新药品收入每年增长近20%的业绩考核目标，确定了公司聚焦创新资产，坚持高质量发展的行动方向。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026060300034628.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0188","600196","BK0175","BK0096","BK0196","BK1191","BK1515","BK0183","02196","BK0012","BK0028","BK1593","BK0060","BK0187","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640597503","title":"医美概念承压 巨子生物(02367)领跌4.08% 机构指敷料药店渠道红利消退、行业进入存量竞争","url":"https://stock-news.laohu8.com/highlight/detail?id=2640597503","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2640597503?lang=zh_cn&edition=full","pubTime":"2026-06-03 13:39","pubTimestamp":1780465177,"startTime":"0","endTime":"0","summary":"金吾财讯 | 港股医美概念普跌，截至发稿，巨子生物(02367)跌4.08%，医思健康(02138)跌3.66%，复星医药(02196)跌3.16%，康哲药业(00867)跌2.53%，四环医药(00460)跌2.08%，三生制药(01530)跌2.07%。消息面上，华龙证券新近研究指，当前医美行业政策端医保支付监管收紧，医美敷料药店渠道红利消退，行业合规化监管持续深化；医美行业进入存量竞争，循证诊疗、合规经营、精细化运营成为机构发展核心方向。产业端AI智能设备、数字化服务加速在美业线下场景渗透，数智化转型成为行业新趋势，区域美业展会加速全产业链资源整合与模式创新。","market":"us","thumbnail":"https://static.szfiu.com/news/20250110/MDc3ODQ0ZjRmZjY3NDY3NWE2ZmExZWEzMjkyYmRjMmI4NjI3MTMyNDA2NzU1.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250110/MDc3ODQ0ZjRmZjY3NDY3NWE2ZmExZWEzMjkyYmRjMmI4NjI3MTMyNDA2NzU1.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1982967","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","SG9999015945.SGD","02367","SG9999015952.SGD","IE00BVYPNQ40.USD","BK1207","SG9999015986.USD","BK1593","BK1600","LU2488822045.USD","SG9999004220.SGD","BK1583","IE00BVYPNP33.GBP","BK1511","HK0000165453.HKD","02196","BK1191","02138","00867","SG9999004311.SGD","SG9999015978.USD","01530","BK1215","IE00BGHQDM52.EUR","00460","IE00BMCWC346.EUR","BK1515","IE00BYV24P56.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640673927","title":"创新药研发及商业化加速 复星国际(00656)“最强估值锚点”夯实确定性","url":"https://stock-news.laohu8.com/highlight/detail?id=2640673927","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2640673927?lang=zh_cn&edition=full","pubTime":"2026-06-03 09:30","pubTimestamp":1780450200,"startTime":"0","endTime":"0","summary":"创新药步入收获期，全球市场商业潜力加速兑现近年来，在创新及全球化两大引擎的推动下，复星的创新药持续在全球市场商业放量，成为其重要的增长极。随着复星创新药进入商业化放量周期，其利润贡献和估值支撑能力都在明显增强。其中，花旗着重指出，基于向好的基本面情况，预计复星国际2026年业绩表现强劲。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1449419.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1191","02196","BK1230","00656","BK1161","BK1574","159992","BK1515","BK1593","06978"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640983626","title":"股市必读：复星医药（600196）5月29日董秘有最新回复","url":"https://stock-news.laohu8.com/highlight/detail?id=2640983626","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2640983626?lang=zh_cn&edition=full","pubTime":"2026-06-01 01:28","pubTimestamp":1780248491,"startTime":"0","endTime":"0","summary":"截至2026年5月29日收盘，复星医药报收于23.25元，上涨2.2%，换手率1.24%，成交量26.17万手，成交额6.07亿元。复星医药关于参与设立私募股权投资基金进展的公告2026年5月28日，复星医药控股企业苏州君明与其他7方投资人签订《杭州基金合伙合同》，共同设立杭州基金。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026060100000614.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0012","BK0028","BK0175","BK0239","BK1593","BK0188","BK1191","BK0187","BK0060","BK0196","BK1515","BK0096","02196","BK0183","600196"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2639601490","title":"每周股票复盘：复星医药（600196）复宏汉霖帕妥珠单抗获批上市","url":"https://stock-news.laohu8.com/highlight/detail?id=2639601490","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2639601490?lang=zh_cn&edition=full","pubTime":"2026-05-31 01:57","pubTimestamp":1780163829,"startTime":"0","endTime":"0","summary":"截至2026年5月29日收盘，复星医药报收于23.25元，较上周的23.4元下跌0.64%。本周关注点公司公告汇总：复宏汉霖帕妥珠单抗注射液获国家药监局批准上市。复星医药控股子公司复宏汉霖自主研发的帕妥珠单抗注射液获国家药品监督管理局批准上市，适应症覆盖早期乳腺癌和转移性乳腺癌。该药品为帕妥珠单抗生物类似药，已获美国FDA、欧盟委员会批准，并获加拿大卫生部受理。2025年中国境内帕妥珠单抗产品销售额约为27.28亿元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026053100000394.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["HK0000320223.HKD","HK0000165453.HKD","BK1593","BK0028","02196","BK0188","BK0096","BK0183","02696","HK0000306701.USD","BK1515","HK0000320264.USD","HK0000306685.HKD","BK0196","BK0012","BK0239","BK1161","BK0175","600196","BK0187","BK0060","BK1191"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2639622925","title":"智翔金泰GR1803授权复星医药：18.2亿元交易落地，股价为何大跌逾9%？","url":"https://stock-news.laohu8.com/highlight/detail?id=2639622925","media":"每日经济新闻","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2639622925?lang=zh_cn&edition=full","pubTime":"2026-05-29 19:56","pubTimestamp":1780055789,"startTime":"0","endTime":"0","summary":"一则涉及高达18.2亿元的重磅授权公告，并未给智翔金泰（SH688443）的股价带来提振。5月29日，公司股价开盘即震荡走低，盘中最大跌幅超过9%，截至收盘报26.80元，单日下跌9.18%，总市值回落至约98.27亿元。而在前一日晚间，公司刚刚宣布与复星医药控股子公司药友制药就核心管线GR1803达成大中华区独家授权合作。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202605293754629730.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202605293754629730.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK0175","BK1593","BK0096","BK0012","BK0196","BK0183","600196","BK0028","BK1515","02196","BK0239","BK0187","BK0060","BK0188","BK1191"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2639962860","title":"复星医药(600196.SH)控股子公司帕妥珠单抗注射液获注册批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2639962860","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2639962860?lang=zh_cn&edition=full","pubTime":"2026-05-29 16:41","pubTimestamp":1780044063,"startTime":"0","endTime":"0","summary":"2、转移性乳腺癌：与曲妥珠单抗和多西他赛联合，适用于既往未接受过针对转移性乳腺癌的抗HER2治疗或者化疗的HER2阳性、转移性或不可切除的局部复发性乳腺癌患者治疗。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1447733.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0060","BK0239","BK1191","BK0183","BK0012","BK1515","BK0196","BK1593","600196","BK0028","BK0175","02196","BK0187","BK0188","BK0096"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638691435","title":"复星医药（600196）披露控股子公司签订许可协议的公告，5月28日股价下跌2.44%","url":"https://stock-news.laohu8.com/highlight/detail?id=2638691435","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2638691435?lang=zh_cn&edition=full","pubTime":"2026-05-28 22:14","pubTimestamp":1779977657,"startTime":"0","endTime":"0","summary":"截至2026年5月28日收盘，复星医药报收于22.75元，较前一交易日下跌2.44%，最新总市值为607.52亿元。该股当日开盘23.21元，最高23.35元，最低22.64元，成交额达3.75亿元，换手率为0.77%。近日，复星医药披露《关于控股子公司签订许可协议的公告》。该事项已经公司第十届董事会第三十一次会议审议通过。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026052800043097.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["600196","BK0188","BK0183","BK0239","02196","BK0028","BK0012","BK1191","BK0060","BK0096","BK0175","BK0196","BK0187","BK1515","BK1593"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638102669","title":"复星医药最新公告：控股子公司获智翔金泰GR1803双抗许可总付款上限6亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=2638102669","media":"证券之星","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2638102669?lang=zh_cn&edition=full","pubTime":"2026-05-28 17:26","pubTimestamp":1779960418,"startTime":"0","endTime":"0","summary":"复星医药(600196.SH)公告称，公司控股子公司药友制药与智翔金泰签订许可协议，获授予GR1803双特异性抗体在中国境内及港澳台地区的临床开发、商业化独占权利及生产排他权利，并将作为该产品的上市许可持有人。药友制药将向智翔金泰支付至多6亿元，包括首付款3亿元、上市里程碑2.5亿元及技转里程碑0.5亿元，并基于年度净销售额支付销售里程碑及销售提成。GR1803拟用于治疗多发性骨髓瘤、系统性红斑狼疮等，其附条件上市申请已获国家药监局受理并纳入优先审评。本次许可旨在丰富公司在血液瘤领域的产品管线。以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。相关 ETF","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026052800030921.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0196","BK0187","BK0239","BK1593","BK0175","BK0012","BK1515","BK0028","BK0188","BK1191","02196","600196","BK0096","BK0060","BK0183"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.fosunpharma.com","stockEarnings":[{"period":"1week","weight":-0.0031},{"period":"1month","weight":-0.11},{"period":"3month","weight":-0.1692},{"period":"6month","weight":-0.2192},{"period":"1year","weight":-0.0206},{"period":"ytd","weight":-0.1765}],"compareEarnings":[{"period":"1week","weight":-0.0029},{"period":"1month","weight":-0.0566},{"period":"3month","weight":-0.0588},{"period":"6month","weight":-0.0394},{"period":"1year","weight":0.018},{"period":"ytd","weight":-0.0443}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"上海复星医药（集团）股份有限公司是一家主要从事医药产品研发、制造与销售的中国公司。该公司经营五个分部。制药分部主要从事创新药、成熟医药产品制造和疫苗业务。医疗器械与医学诊断分部主要从事分子诊断、免疫诊断、微生物诊断等医疗美容器械的制造和销售。医疗健康服务分部主要从事线上线下一体化医疗服务平台的经营。医药分销和零售分部主要从事医药产品的批发零售。其他分部从事其他医药相关业务。该公司的产品主要用于肿瘤、免疫、中枢神经等治疗领域。","yearOnYearQuotes":[{"month":1,"riseRate":0.428571,"avgChangeRate":-0.044492},{"month":2,"riseRate":0.714286,"avgChangeRate":0.036178},{"month":3,"riseRate":0.571429,"avgChangeRate":0.044258},{"month":4,"riseRate":0.357143,"avgChangeRate":0.026005},{"month":5,"riseRate":0.428571,"avgChangeRate":0.024934},{"month":6,"riseRate":0.428571,"avgChangeRate":-0.02851},{"month":7,"riseRate":0.615385,"avgChangeRate":0.027595},{"month":8,"riseRate":0.307692,"avgChangeRate":-0.041651},{"month":9,"riseRate":0.461538,"avgChangeRate":0.011609},{"month":10,"riseRate":0.461538,"avgChangeRate":0.020359},{"month":11,"riseRate":0.428571,"avgChangeRate":0.034495},{"month":12,"riseRate":0.428571,"avgChangeRate":0.015123}],"exchange":"SEHK","name":"复星医药","nameEN":"FOSUN PHARMA"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.0","shortVersion":"4.44.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"复星医药(02196)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供复星医药(02196)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"复星医药,02196,复星医药股票,复星医药股票老虎,复星医药股票老虎国际,复星医药行情,复星医药股票行情,复星医药股价,复星医药股市,复星医药股票价格,复星医药股票交易,复星医药股票购买,复星医药股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"复星医药(02196)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供复星医药(02196)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}